Articles tagged with: Fundraiser
News »
MDX-1097 Receives Orphan Drug Status For Multiple Myeloma – The Australian bio-therapeutic company Immune System Therapeutics announced last week that it has received orphan drug designation from the United States Food and Drug Administration (FDA) for its investigational drug MDX-1097. MDX-1097 is an antibody that binds to certain proteins on the surface of myeloma cells, triggering the immune system to kill the cancer cells. The FDA uses the orphan drug designation to promote the development of new treatments for rare diseases that affect fewer than 200,000 individuals in the United States. The orphan drug status provides the developer of the drug with multiple benefits, including funding for clinical trials, accelerated FDA approval, and marketing exclusivity for up to seven years. For more information, please see the Immune System Therapeutics press release.
MD Anderson Cancer Center Announces Start Of Phase 1 Trial With Carfilzomib Plus Panobinostat In Myeloma – The MD Anderson Cancer Center announced last week that it will be starting a Phase 1 trial in early August to determine the highest tolerable dose levels of carfilzomib in combination with panobinostat in relapsed and refractory multiple myeloma patients. The safety of the combination treatment will also be assessed. Carfilzomib, which belongs to the same class of drugs as Velcade (bortezomib), is a new drug from Onyx Pharmaceuticals that is currently being investigated as a potential treatment for multiple myeloma. Panobinostat is an oral experimental cancer drug that is being developed by Novartis. For more information, please see the clinical trial description.
Music Against Myeloma – On Wednesday, July 13, several bands will play at Greenhouse in Manhattan to raise awareness and funds for multiple myeloma. The event starts at 8 p.m. and will feature live bands, drink specials, cupcakes, and more. All proceeds will go to the International Myeloma Foundation. For more information and tickets, please see the Music Against Myeloma website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
News »
U.K. Agency Recommends Velcade and Thalidomide For Myeloma Patients – The National Institute of Clinical Excellence (NICE), the agency that decides which treatments will be funded for patients in England and Wales, released a final draft guidance on June 2 recommending that Velcade (bortezomib) and thalidomide (Thalomid) can be used as first-line treatments for multiple myeloma patients who are not candidates for stem cell transplants. Both drugs are currently recommended as second-line treatments. The final guidance deciding the use of Velcade and thalidomide in the U.K. is expected later this year. For more information, please see the NICE website.
15th Congress Of The European Hematology Association – As a reminder to Beacon readers, the European Hematology Association (EHA) will hold its 15th meeting from June 10 to 13 in Barcelona, Spain. European researchers and physicians will meet to present the latest research findings about multiple myeloma and other blood disorders. The Myeloma Beacon will also be covering the event on its website. For more information, please visit the EHA Congress website.
MMRF Race For Research – On June 13, the Multiple Myeloma Research Foundation (MMRF) will hold a Race For Research 5K Walk/Run in New Canaan, CT, to raise awareness and funds for multiple myeloma research. Registration is scheduled for 7:30 a.m., and the race starts at 9 a.m. For more information, please see the MMRF website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
News »
Fred Hutchinson Cancer Center To Field Questions At The Beacon’s Forums This Week – Dr. William Bensinger, myeloma expert at the Fred Hutchinson Cancer Center in Seattle, WA, will be be responding to medical questions posted in the Myeloma Beacon’s forums this week. Readers who have not yet visited the Beacon’s new myeloma discussion forums are encouraged to do so, as they already contain a number of informative postings about topics such as myeloma treatment options, managing treatment side effects, and alternative myeloma therapies.
Treanda Combination Therapy Enters Phase 1B/2 Trial For Multiple Myeloma – Last week, the Multiple Myeloma Research Consortium (MMRC) announced the start of a Phase 1B/2 clinical trial that will evaluate a combination of Treanda (bendamustine), Revlimid (lenalidomide) and dexamethasone (Decadron) in relapsed multiple myeloma patients. Treanda is already approved in Germany in combination with prednisone for the treatment of multiple myeloma. In the United States, the drug is approved for the treatment of chronic lymphocytic leukemia and certain lymphomas. For more information, see the MMRC press release or the clinical trial description.
MMRF Kicks Off Race For Research 5K Walk/Run Series – On April 25, the Multiple Myeloma Research Foundation (MMRF) will kick off its annual Race For Research 5K Walk/Run series to raise awareness and funds for multiple myeloma research. The events will take place in eight cities across the Unites States. The first one is scheduled for April 25 in San Francisco. For more information and registration details, see the MMRF Web site.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
News »
Myeloma Experts From University Of Arkansas Answer Questions At The Myeloma Beacon Forums This Week – Dr. Bart Barlogie and Dr. Bijay Nair, myeloma experts from the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences will be answering medical questions posted to the forums at the Myeloma Beacon this week. Readers can post their questions and review answers from other myeloma experts by visiting the Myeloma Beacon Forums.
MMRF Grants Funding To Intellikine and Tragara Pharmaceuticals For Novel Myeloma Treatments – The Multiple Myeloma Research Foundation (MMRF) announced last week that it will award Intellikine and Tragara Pharmaceuticals, two biotech companies based in Southern California, with $1 million each for the development of two new compounds for the treatment of multiple myeloma. Intellikine’s INK128 and Tragara Pharmaceuticals’ TG02 have both shown potential for multiple myeloma in pre-clinical studies. For more information, please see the MMRF press release.
5th Annual “Music Against Myeloma” Fundraiser To Be Held In NYC – On April 22, special musical performances will take place during the 5th annual “Music Against Myeloma” fundraiser to the benefit of the International Myeloma Foundation. The event will take place at BLVD in New York City from 7 to 10 p.m. Advance tickets are $40. Please see the Music Against Myeloma Web site for additional information and to purchase tickets.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
News »
UAMS Receives $19.5 Million Grant For Multiple Myeloma Program – The Myeloma Institute at the University of Arkansas for Medical Sciences (UAMS) will receive $19.5 million over five years from the National Cancer Institute (NCI). The grant is the fourth renewal of continuous funding from the NCI and will allow for continued research on myeloma and the development of new treatments. For more information, please visit the UAMS Web site.
MMRF’s Fall Gala Raises Over $1.8 Million For Multiple Myeloma Research – The Multiple Myeloma Research Foundation (MMRF) raised more than $1.8 million at its annual Fall Gala. The funds will support myeloma research and the development of new treatments. For more information, please visit the MMRF Web site.
3rd Annual Comedy Celebration – The International Myeloma Foundation’s (IMF) 3rd annual Comedy Celebration will take place on November 7 at The Wilshire Ebell Theatre & Club in Los Angeles. It will benefit the Peter Boyle Memorial Fund and will feature Ray Romano, Jimmey Kimmel, and Bob Saget, along with many others. For more information, please visit the IMF Web site.
World Run Day – On November 8, a 5K run will take place in multiple locations around the world. Among the charities which will receive funds from donations is the Multiple Myeloma Research Foundation (MMRF). For more information, please visit the World Run Day Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
